<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221360</url>
  </required_header>
  <id_info>
    <org_study_id>A92_02BE1920</org_study_id>
    <nct_id>NCT04221360</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of High Dose CKD-375 and D390 in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of
      CKD-375.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the
      Pharmacokinetics and Safety/Tolerability After Oral Administration of High Dose CKD-375 and
      D390 in Healthy Adults.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 29, 2020</start_date>
  <completion_date type="Anticipated">June 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum plasma concentration of D390 and CKD-375</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of D390 and CKD-375</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of D390 and CKD-375</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time to maximum plasma concentration of D390 and CKD-375</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half-life of D390 and CKD-375</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Apparent volume of distribution of D390 and CKD-375</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of D390 and CKD-375</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Apparent clearance of D390 and CKD-375</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D390
Period 2: CKD-375</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-375
Period 2: D390</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-375</intervention_name>
    <description>Test drug, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D390</intervention_name>
    <description>Reference drug, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult who is 19 ~ 55 years at the time of screening

          2. Body weight more than 55 kg for male and more than 50kg for female

          3. BMI more than 18.5 kg/m2 or less than 27.0 kg/m2

          4. Females must be menopause or surgical infertility

          5. Males who have consented to the use of appropriate pregnancy contraceptive methods up
             to 28 days after the last investigational product and not to provide sperm

          6. Subjects who voluntarily decided to participate and informed consent based upon
             understanding on the study.

        Exclusion Criteria:

          1. Subjects who have a history of clinically significant hepatic, renal, nervous, immune,
             respiratory, urinary, digestion, endocrine, hemato-oncology, cardiovascular systemic
             disease or psychosis disorder

          2. Subjects who has clinically significant dehydration or is vulnerable to dehydration
             due to poor oral intake

          3. Subjects who underwent intravenous administration of radioactive iodine contrast
             agents (e.g., intravenous urography, venous cholangiography, angiography, computed
             tomography using contrast agents, etc.) within 48 hours prior to the first dose of the
             investigational product

          4. Subjects who have a significant urinary tract infection or have such a history

          5. Subjects who have genetic problems such as galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          6. Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative
             colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may
             affect the absorption of the drug

          7. Subjects who have a history of clinically significant hypersensitivity to drugs or
             additives, including components of the investigational product (empagliflozin,
             metformin)

          8. Subjects who are deemed unsuitable as subjects in the screening test performed within
             28 days before the administration of investigational product

               -  AST, ALT&gt; UNL(Upper Normal Limit)x1.25

               -  Total bilirubin &gt; UNL(Upper Normal Limit)x1.5

               -  eGFR (Estimated Glomerular Filtration Rate) &lt;60 mL / min / 1.73m2 using the MDRD
                  (Modification of Diet in Renal Disease) formula

               -  Positive immunologic serological tests (hepatitis B test, hepatitis C test, human
                  immunodeficiency virus (HIV) test, syphilis test)

               -  After resting for more than 5 minutes, systolic blood pressure&gt; 150 mmHg or &lt; 90
                  mmHg, diastolic blood pressure&gt; 100 mmHg or &lt;50 mmHg

          9. Subjects who have had a history of drug abuse within one year of screening or have
             tested positive on urine drug screening test

         10. Pregnant or lactating women

         11. Subjects who have consistently excessively smoked or consumed caffeine or alcohol
             (caffeine:&gt; 5 cups / day, alcohol:&gt; 210 g / week, cigarettes:&gt; 10 cigarettes / day) or
             cannot stop smoking, consuming caffeine and alcohol during hospitalization

         12. Subjects who took any of the following drugs except for topical without serious
             systemic absorption and hormonal contraceptives and are deemed that the administered
             drug may affect in the study or the safety of the subject by the investigator

               -  Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first
                  administration of the investigational drug

               -  Over-the-counter (OTC) drugs, including health foods and vitamin preparations,
                  within 7 days of the first dose of the investigational product

               -  Drugs administered by depot injection or through iomplantation in the human body
                  within 30 days of the first dose of investigational product

         13. Subjects who have received the investigational product by participating in other
             clinical trials (including bioequivalence studies) within 180 days before the first
             dose of the investigational product (For biological agents, this may be based on a
             longer period of time, considering the half-life)

         14. Subjects who donated whole blood within 60 days before the first dose of the
             investigational product or donated component blood donation within 30 days

         15. Subjects who were deemed to be inappropriate to participate in the study by the
             investigator judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Soo Park, M.D., Ph.D.</last_name>
    <phone>+82-2-2228-0401</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

